2 Information about mexiletine

Marketing authorisation indication

2.1 Mexiletine (Namuscla, Lupin) is indicated 'for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price is £5,000 per 100×167 mg capsules (excluding VAT; BNF online, accessed September 2021). The company has a commercial arrangement. This makes mexiletine (Namuscla) available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)